AB Science announces a capital increase of 5.0 million euros

AB Science SA has successfully completed a capital increase of €5.0 million through the issuance of 5,368,725 ordinary shares with warrants. This transaction was subscribed by qualified European investors. AB Science CEO Alain Moussy expressed his satisfaction with this fundraising, intended to finance the phase 2 clinical development of the AB8939 microtubule program.

The new shares, issued at a price of 0.93132 euros, represent a 10% discount compared to the weighted average of the last three trading sessions of Euronext Paris. Following this transaction, the company's share capital will consist of 64,589,428 shares.

These funds will provide AB Science with the resources necessary to finance its activities over the next twelve months, including the clinical development of masitinib in amyotrophic lateral sclerosis and other orphan diseases.